Molecular Insight Pharmaceuticals Augments Research and Development Capability with Key Hire and Appointment of Two New Board Members.CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals announced today that Nicholas Borys, M.D. has joined the company as Chief Medical Officer. Dr. Borys' experience includes extensive work in the development of imaging pharmaceuticals for industry leading companies. The company also reported that Molecular Insight's shareholders have elected two new members to its board of directors. These new directors, Kim D. Lamon M.D., Ph.D., President and Chief Scientific Officer of Valeant Pharmaceuticals International Valeant Pharmaceuticals International is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. and Harry Stylli, Ph.D., President and Chief Executive Officer of Xencor, Inc. have outstanding track records in researching, developing and commercializing biopharmaceutical technologies and products. "We are extremely pleased that Dr. Nick Borys will lead our development team as we increase the number and scope of clinical studies supporting our advancing new product pipeline. Dr. Borys' proven ability to build and lead teams that develop highly successful imaging pharmaceuticals is an asset of immediate importance for the company," said David S. Barlow, Chairman & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Molecular Insight Pharmaceuticals. "We are also pleased that Drs. Lamon and Stylli have joined our board as active contributors to our research and development efforts. They will add significant value to the development and implementation of our R&D strategies." As Chief Medical Officer at Molecular Insight, Dr. Borys will oversee the clinical development and NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any submission of BMIPP, the company's lead molecular imaging candidate. The company anticipates that BMIPP's recently initiated Phase 2b clinical trial will be followed by the pivotal Phase 3 study in 2005 and NDA submission in 2006. Dr. Borys will also oversee the clinical development programs for Molecular Insight's pipeline of molecular imaging and targeted radiotherapeutic ra·di·o·ther·a·peu·tic adj. Relating to radiotherapy or to radiotherapeutics. candidates. --Dr. Nicholas Borys joined Molecular Insight with 16 years of experience in pharmaceutical development. His background includes strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. and management of all phases of clinical development for Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) approval. Most recently he held the Chief Medical Officer position at Taiho Pharma where he was responsible for clinical development worldwide. His molecular imaging experience includes senior development positions at Bracco Diagnostics and a six year tenure at Amersham Healthcare, Inc. where he was Director of Medical Affairs and oversaw development of cardiovascular, oncology and neurology neurology (n  rŏl`əjē, ny–), study of the morphology, physiology, and pathology of the human nervous system. products.--Dr. Kim Lamon, President and Chief Scientific Officer of Valeant Pharmaceuticals with U.S. headquarters in Costa Mesa, California Costa Mesa is a suburban middle class city in Orange County, California, United States. The population was 108,724 at the 2000 census. Since its incorporation in 1953, the city has grown from a semi-rural farming community of 16,840 to a suburban city with an economy based on , was previously CEO of Ribopharm, Inc. before it was reacquired by Valeant in 2003. His extensive experience includes serving as Corporate Senior Vice President and Group President of Covance Clinical and Periapproval Services, a division of Covance, Inc., a world leading clinical research organization; Senior Vice President of Science and Technology for Corning Life Sciences, Inc.; and as Senior Vice President and Executive Medical Director for Rhone Poulenc Rorer (now Aventis, Inc.) where he also held other senior management positions at the company. --Dr. Harry Stylli is President and CEO of Xencor, Inc., a privately held biotechnology company in Monrovia, California Monrovia is a city located in the foothills of the San Gabriel Mountains in the San Gabriel Valley of Los Angeles County, California, United States. The population was 36,929 at the 2000 census. focused on applying its proprietary protein design platform to greatly enhance the ability of antibodies to modulate To insert a data signal into a carrier wave or direct current. See modulation. the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Xencor is forward integrating to the clinic with next generation antibodies and receptor selective DN-TNF blockers. His highly distinguished 20 year career in the biopharmaceutical industry includes serving as founding President and CEO of CovX Pharmaceuticals and as co-founder and President of Aurora Biosciences, where he played a pivotal role in its growth and acquisition by Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. . From 1987 to 1995 Dr. Stylli held varying positions of increasing responsibility in the global discovery organization of GlaxoSmithKline. He also serves on the board of Scitegic, Inc. a privately held bioinformatics company.
Molecular Insight Board of Directors
David S. Barlow Chairman & CEO
Molecular Insight Pharmaceuticals, Inc.
John W. Babich, Ph.D. President & CSO
Molecular Insight Pharmaceuticals, Inc.
William C. Eckelman, Ph.D. Chief of the Positron Emission
Tomography (PET) Department at the
Clinical Center NIH
Daniel R. Frank Managing Director
Cerberus Capital Management, L.P.
Kim D. Lamon, M.D., Ph.D. President & CSO
Valeant Pharmaceuticals International
James W. Poitras President & CEO
Highland Laboratories, Inc.
Harry Stylli, Ph.D. President & CEO, Xencor, Inc.
About Molecular Insight Pharmaceuticals Molecular Insight Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on leveraging its proprietary technology platforms in molecular medicine to develop innovative pharmaceuticals to diagnose and treat disease. These products are designed to improve the management of disease by targeting, visualizing, treating and monitoring disease at the molecular level. The Company, based in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. , has established a strong pipeline of molecular imaging candidates focused on the large and growing markets in cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. , oncology and neurology. The Company is also applying its platform technologies to develop targeted radiotherapeutics for the treatment of cancer. www.molecularinsight.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion